Trial completion • Checkpoint inhibition • Checkpoint block
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK mutation
|
Tecentriq (atezolizumab) • Cyramza (ramucirumab)